Indication

Carcinoma of cervix

Carcinoma of the cervix is a malignant epithelial neoplasm arising from the uterine cervix, primarily occurring at the squamocolumnar junction between the ectocervix and endocervical canal. Read more about Carcinoma of cervix

31 drugs 28 manufacturers

Advertisement

Drugs that treat it

Common Carcinoma of cervix therapies.

Showing 10–18 of 31 drugs

KEYTRUDA (pembrolizumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT MELANOMA·+36
Merck Sharp & Dohme

TOPOTECAN HCL

ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS·SMALL CELL LUNG CARCINOMA·+3
APP/FRESENIUS K

TOPOTECAN HCL

ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS·SMALL CELL LUNG CARCINOMA·+3
INGENUS PHARMAC

TOPOTECAN HCL

ANTINEOPLASTIC - TOPOISOMERASE I INHIBITORS·SMALL CELL LUNG CARCINOMA·+3
Hospira
Filter & compare in the drug finder →Opens the drug finder with Carcinoma of cervix preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Carcinoma of cervix.

Carcinoma of the cervix is a malignant epithelial neoplasm arising from the uterine cervix, primarily occurring at the squamocolumnar junction between the ectocervix and endocervical canal.

Pathophysiologically driven in the vast majority of cases by persistent infection with high-risk human papillomavirus genotypes, it commonly presents histologically as squamous cell carcinoma or adenocarcinoma.

Although early stages are frequently asymptomatic and detected via routine cytological or molecular screening, advanced disease manifests with abnormal vaginal bleeding, postcoital spotting, watery or foul discharge, and pelvic pain, with the potential for direct local invasion into surrounding pelvic structures and lymphatic dissemination.

Personalize your experience

Follow Carcinoma of cervix and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it